Phase 3 Clinical Trials With Primary Completion Dates in March 2017
This is a list of Phase 3 trials with primary completion dates in March 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ARQL||ArQule, Inc.||2017-03-01||Phase 3||NCT01755767||Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy|
|CLVS||Clovis Oncology, Inc.||2017-03-01||Phase 3||NCT01968213||A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer|
|FGEN||FibroGen, Inc||2017-03-01||Phase 3||NCT02174627||Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis|
|IONS||Ionis Pharmaceuticals, Inc.||2017-03-01||Phase 3||NCT01737398||Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy|
|LXRX||Lexicon Pharmaceuticals, Inc.||2017-03-01||Phase 3||NCT02531035||A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadaquate Glycemic Control With Insulin Therapy Alone|
|RARE||Ultragenyx Pharmaceutical Inc.||2017-03-01||Phase 3||NCT02526160||Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)|
|SUPN||Supernus Pharmaceuticals, Inc.||2017-03-01||Phase 3||NCT02618408||Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)|
|TARO||Taro Pharmaceutical Industries Ltd.||2017-03-01||Phase 3||NCT02932462||Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis|
|TARO||Taro Pharmaceutical Industries Ltd.||2017-03-01||Phase 3||NCT02618759||Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis|
|TARO||Taro Pharmaceutical Industries Ltd.||2017-03-01||Phase 3||NCT02595073||Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis|